Our Approach
Rigorous Selection
Each program begins with validated human biology, well-characterized pharmacology, and a clear translational rationale. We also weigh market dynamics early to ensure each asset aligns with a clear opportunity.
Precision Development
We integrate AI-enabled trial design, operational and outcomes modeling to accelerate learning and reduce uncertainty. Multi-omic, clinical, and real-world evidence are unified to support development decisions.
Execution Excellence
Resources are deployed deliberately—focused on experiments that deliver tangible value. We prioritize rapid, informative studies that derisk programs ahead of larger investments.
Value Inflection
Programs are built around clear and data-validated points of value creation. Every milestone is structured to create optionality for co-development, out-licensing or next-phase financing.
Focus Areas
Cardiovascular disease
Cardiovascular disease remains the leading cause of reduced health and death globally, driven by dyslipidemia, inflammation, and metabolic dysfunction.
Sarawa focuses on mechanisms that lower residual risk beyond standard lipid control, including genetically validated targets and inflammatory signaling pathways that drive vascular injury and plaque progression.
Through multi-modal, data-anchored development and targeted clinical design, we aim to redefine how atherosclerotic cardiovascular disease is prevented and treated.
Aging, Fibrosis & Inflammation
Aging, fibrosis, and chronic inflammation are linked by shared biology such as mitochondrial stress and impaired tissue repair. Persistent immune activation accelerates decline and promotes progressive fibrosis.
Sarawa's programs target this intersection by focusing on molecular nodes where inflammation originates and propagates, prioritizing mechanisms with strong translational evidence.
By modulating these mechanisms in well-designed clinical trials, we aim to restore immune balance and slow or reverse the tissue dysfunction that underlies multiple age-related diseases.